Latest Insights - page 58 | BiopharmaTrend

Blackrock Neurotech Restores ALS Patient's Speech Using Brain-Computer Interface

Blackrock Neurotech has successfully restored speech for an ALS patient through a brain-computer interface (BCI) implant, achieving a communication rate of 62 words per minute. Amyotrophic lateral sclerosis (ALS) is …

Continue ›››

NanoViricides Prepares for Phase II Clinical Trial of Broad-Spectrum Antiviral NV-387

NanoViricides, Inc., a clinical-stage biopharmaceutical company, is advancing its lead drug candidate, NV-387, towards a Phase II clinical trial. NV-387, designed as a broad-spectrum antiviral therapy, is being developed to …

Continue ›››

Walgreens Partners with U.S. Government to Advance Decentralized Clinical Trials

Walgreens has entered into a partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), to enhance decentralized …

Continue ›››

Indica Labs Introduces HALO AI Apps for Enhanced Life Sciences Image Analysis

Indica Labs has launched a new suite of HALO AI Apps, expanding their AI capabilities for life sciences. These pre-trained tissue classifiers and cell phenotypers are designed for tissue-based research …

Continue ›››

Pathos AI Acquires Brain-Penetrant PRMT5 Inhibitor for Precision Cancer Therapy

Pathos AI has announced the acquisition of a worldwide license for PRT811, a SAM-competitive PRMT5 inhibitor, from Prelude Therapeutics. Renamed P-500, this potent, selective, and orally bioavailable brain-penetrant drug is …

Continue ›››

Pfizer Appoints New Chief AI Officer to Enhance Digital Innovation

As Amber Jackson reports for Technology Magazine, Pfizer has appointed Berta Rodriguez-Hervas as its new Chief AI and Analytics Officer, signaling the company's commitment to advancing its artificial intelligence (AI) …

Continue ›››

23andMe Shifts Focus to Telehealth GLP-1 Prescriptions Amid Strategic Realignment

Consumer genetic testing company 23andMe has announced a strategic shift, closing its drug discovery division while expanding into the rapidly growing GLP-1 drug market. The company plans to offer GLP-1 …

Continue ›››

Medable Introduces New eCOA Platform to Streamline Clinical Trial Launches

Medable Inc., a technology platform provider specializing in clinical trials, has announced the launch of Medable Studio, an all-in-one application designed to streamline the configuration, translation, validation, and deployment of …

Continue ›››

Basecamp Research Partners with Cameroon to Share Benefits from Genetic Data Use in Landmark Agreement

Basecamp Research, a London-based biotech company specializing in AI-driven design of proteins and other biological systems, has entered into a groundbreaking access and benefit-sharing (ABS) partnership with the government of …

Continue ›››

Veridix AI Introduces Protocol Digitization to Streamline Clinical Trial Study Builds

Veridix AI, a subsidiary of the Emmes Group, has unveiled its latest technological advancement aimed at enhancing the efficiency of clinical trials through protocol digitization. Integrated within the company's eClinical …

Continue ›››

OpenFold Consortium Expands with Six New Members to Strengthen Open-Source AI Tools for Drug Discovery

OpenFold, a prominent non-profit AI research consortium dedicated to developing free and open-source tools for biology and drug discovery, has announced the addition of six new industry members: Astex Pharmaceuticals, …

Continue ›››

Persist AI and Nivagen Collaborate on AI-Enhanced Manufacturing for Long-Acting Injectables

Persist AI and Nivagen have announced a strategic collaboration aimed at advancing the manufacturing process for long-acting injectable (LAI) drugs. This partnership seeks to combine Persist AI's expertise in AI-driven …

Continue ›››